261 related articles for article (PubMed ID: 10803677)
21. Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W.
Vreken P; Van Kuilenburg AB; Meinsma R; van Gennip AH
Hum Genet; 1997 Dec; 101(3):333-8. PubMed ID: 9439663
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.
van Kuilenburg AB; Häusler P; Schalhorn A; Tanck MW; Proost JH; Terborg C; Behnke D; Schwabe W; Jabschinsky K; Maring JG
Clin Pharmacokinet; 2012 Mar; 51(3):163-74. PubMed ID: 22339448
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
Raida M; Schwabe W; Häusler P; Van Kuilenburg AB; Van Gennip AH; Behnke D; Höffken K
Clin Cancer Res; 2001 Sep; 7(9):2832-9. PubMed ID: 11555601
[TBL] [Abstract][Full Text] [Related]
24. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.
Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
Pharmacogenetics; 2002 Oct; 12(7):555-8. PubMed ID: 12360106
[TBL] [Abstract][Full Text] [Related]
25. Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography.
Fischer J; Schwab M; Eichelbaum M; Zanger UM
Genet Test; 2003; 7(2):97-105. PubMed ID: 12885330
[TBL] [Abstract][Full Text] [Related]
26. Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population.
Ben Fredj R; Gross E; Chouchen L; B'Chir F; Ben Ahmed S; Neubauer S; Kiechle M; Saguem S
C R Biol; 2007 Oct; 330(10):764-9. PubMed ID: 17905396
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.
van Kuilenburg AB; De Abreu RA; van Gennip AH
Ann Clin Biochem; 2003 Jan; 40(Pt 1):41-5. PubMed ID: 12542909
[TBL] [Abstract][Full Text] [Related]
28. [Mutations in the dihydropyrimidine dehydrogenase gene and their role in 5-fluororuracil intolerance].
Gross E; Seck K; Kiechle M
Zentralbl Gynakol; 2002 Dec; 124(12):574-9. PubMed ID: 12822071
[TBL] [Abstract][Full Text] [Related]
29. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Ogura K
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
[TBL] [Abstract][Full Text] [Related]
30. Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio.
Sistonen J; Büchel B; Froehlich TK; Kummer D; Fontana S; Joerger M; van Kuilenburg AB; Largiadèr CR
Pharmacogenomics; 2014 Sep; 15(13):1653-66. PubMed ID: 25410891
[TBL] [Abstract][Full Text] [Related]
31. Cloning and initial characterization of the human DPYD gene promoter.
Collie-Duguid ES; Johnston SJ; Powrie RH; Milano G; Etienne MC; Rochat B; Watson GC; McLeod HL
Biochem Biophys Res Commun; 2000 Apr; 271(1):28-35. PubMed ID: 10777676
[TBL] [Abstract][Full Text] [Related]
32. Highlight on DPYD gene polymorphisms and treatment by capecitabine (.).
Milano G
Scand J Clin Lab Invest Suppl; 2016; 245():S30-3. PubMed ID: 27454530
[TBL] [Abstract][Full Text] [Related]
33. Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients.
Salgueiro N; Veiga I; Fragoso M; Sousa O; Costa N; Pellon ML; Sanches E; dos Santos JG; Teixeira MR; Castedo S
Genet Med; 2004; 6(2):102-7. PubMed ID: 15017333
[TBL] [Abstract][Full Text] [Related]
34. Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene.
Kuilenburg ABPV; Meijer J; Tanck MWT; Dobritzsch D; Zoetekouw L; Dekkers LL; Roelofsen J; Meinsma R; Wymenga M; Kulik W; Büchel B; Hennekam RCM; Largiadèr CR
Biochim Biophys Acta; 2016 Apr; 1862(4):754-762. PubMed ID: 26804652
[TBL] [Abstract][Full Text] [Related]
35. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.
Mattison LK; Soong R; Diasio RB
Pharmacogenomics; 2002 Jul; 3(4):485-92. PubMed ID: 12164772
[TBL] [Abstract][Full Text] [Related]
36. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.
Ofverholm A; Arkblad E; Skrtic S; Albertsson P; Shubbar E; Enerbäck C
Clin Biochem; 2010 Feb; 43(3):331-4. PubMed ID: 19822137
[TBL] [Abstract][Full Text] [Related]
37. DPYD*2A mutation: the most common mutation associated with DPD deficiency.
Saif MW; Ezzeldin H; Vance K; Sellers S; Diasio RB
Cancer Chemother Pharmacol; 2007 Sep; 60(4):503-7. PubMed ID: 17165084
[TBL] [Abstract][Full Text] [Related]
38. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects.
Ridge SA; Sludden J; Brown O; Robertson L; Wei X; Sapone A; Fernandez-Salguero PM; Gonzalez FJ; Vreken P; van Kuilenburg AB; van Gennip AH; McLeod HL
Br J Clin Pharmacol; 1998 Aug; 46(2):151-6. PubMed ID: 9723824
[TBL] [Abstract][Full Text] [Related]
39. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity.
Van Kuilenburg AB; Vreken P; Beex LV; Meinsma R; Van Lenthe H; De Abreu RA; van Gennip AH
Eur J Cancer; 1997 Nov; 33(13):2258-64. PubMed ID: 9470816
[TBL] [Abstract][Full Text] [Related]
40. Mutations at codon 974 of the DPYD gene are a rare event.
Ridge SA; Brown O; McMurrough J; Fernandez-Salguero P; Evans WE; Gonzalez FJ; McLeod HL
Br J Cancer; 1997; 75(2):178-9. PubMed ID: 9010022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]